Hexima

Hexima R&D per Employee

R&D Spending per Employee of Hexima (HXL.AX) as of Oct 17, 2026.

R&D per Employee

-AUD

Last updated:

R&D Spending per Employee of Hexima is 2026 - AUD. R&D Spending per Employee of Hexima was 2025 - AUD. It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Hexima Stock analysis

What does Hexima do? Hexima Ltd, based in Melbourne, Australia, operates in the Health Care sector within the Biotechnology industry. The company focuses on researching and developing plant defensin peptides for human therapeutics, with its lead candidate pezadeftide targeting fungal nail infections. Hexima is conducting phase II clinical trials for pezadeftide as a treatment for onychomycosis, leveraging its Antifungal Plant Defensin Technology platform to identify antifungal peptides effective against various human fungal pathogens. Listed on 1 December 2020, the company explores applications of its technology for additional fungal diseases. Hexima is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Hexima stock

On Eulerpool you can find the complete historical development of R&D Spending per Employee Hexima since 2006 – with annual values, charts, and detailed analysis.

R&D per employee shows the research and development investment allocated per employee. Higher values indicate innovation-focused companies.

R&D Spending per Employee's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track R&D Spending per Employee's Hexima historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Hexima

All Key Metrics — Hexima